Xencor (XNCR) Stock Forecast: StockMap's 2-Week Call
XNCR stock forecast: StockMap's model makes no two-week call on Xencor after the Nov 13 close: its evidence is split, 4 reasons for and 11 against. Right in 1 of 3 two-week windows on XNCR since Sep 24; by chance, a call on the same dates was right 51% of the time.
Xencor last closed at $37.09, -2.73% on the session.
Against the IVW growth benchmark the position is -1.82% over the forecast window.
Xencor's market cap is $2.78B as of November 13, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -1 (too close to call).
Where XNCR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
15 daily calls for XNCR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Xencor in the 27th percentile on return on equity, where 100 is best.
Xencor is classified under Health Care / Biotechnology.
StockMap tracks Xencor as the 75th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Xencor ranks 85th of 391 in the group, against a group median of -0.24.